Figure02-01 Lateral (side) view of the female pelvis. Figure02-02 The external genital area. Figure02-03 Chart showing the inter-relationship between the major female hormones and the menstrual cycle. Figure02-04 Diagrammatic representation of a timer mechanism for ovum (egg) maturation. Figure02-05 A summary of the pathway in the production of reproductive hormones. Figure02-06 The Hypothalamic-Pituitary-Ovarian Axis. Figure03-01 Examples of congenital (birth) defects of the uterus. Figure04-01 Transvaginal ultrasound examination of the pelvis. Figure04-02 Embracing patient partnership. Figure07-01 Polycystic ovaries. Figure07-02 Glucose tolerance tests of normal and PCOS women. Figure07-03 Insulin response during GTT of normal and PCOS women. Figure08-01 Male pattern hair production in hirsute women. Figure08-02 Flowchart showing investigations for hirsutism. Figure09-01 Essential requirements for fertility. Figure09-02 Flowchart for the investigation and treatment of infertility. Figure09-03 A hysterosalpingogram. Figure10-01 Clomifene - mode of action. Figure10-02 An embryo at the four cell stage. Figure10-03 IVF A typical regimen for treatment and monitoring. Figure10-04 ICSI Intracytoplasmic sperm injection. Figure10-05 IVF pregnancy rate and live birth rates per treatment cycle in the UK. Figure10-06 Annual number of IVF treatment cycles in the UK and North America. Figure10-07 IVF Live Birth Rate by Womens Age. Figure10-08 Cumulative pregnancy rates for fertile couples and infertile couples with treatment. Figure11-01 IVF Live Birth and Multiple Live Birth Rate by the number of embryos transferred. Figure11-02 Still birth and Neonatal Deaths per 1000 birth events. Figure12-01 Miscarriage: Clinical Management Options. Figure14-01 Levonorgestrel Intrauterine System Mirena. Figure15-01 Death rate per million women according to age. Figure18-01 Laparoscopy. Figure18-02 Sterilisation tubal ligation. Figure21-01 The covering layers (epithelia) in the area of the cervix. Figure21-02 Normal squamous cells from the cervix. Figure21-03 Cervical ectopy (erosion). Figure21-04 Cryotherapy (cryocautery) to the cervix. Figure21-05 Cervical speculum to visualise the cervix. Figure21-06 Incidence of cervical cancer and pre-malignant conditions of the cervix from 1955 to 1985. Figure21-07 A pre-malignant cervical smear. Figure21-08 Colposcopy. Figure21-09 Diagrammatic example of colposcopy findings. Figure21-10 Cervical biopsy showing CIN III changes. Figure21-11 Loop cone biopsy of the cervix. Figure23-01 Fibroids. Figure23-02 Endometriosis. Figure23-03 Retroversion of the uterus. Figure23-04 Retroversion of the uterus correction with Hodge pessary. Figure24-01 Polyps of the endometrium and cervix. Figure24-02 Hysteroscopy. Figure24-03 Flowchart showing the investigation and treatment options for menorrhagia (heavy periods). Figure24-04 Abdominal hysterectomy Subtotal & ovary removal options. Figure24-05 Endometrial ablation balloon technique. Figure25-01 PMS symptom chart. Figure25-02 Flowchart Mastalgia treatment options. Figure25-03 Flowchart PMT treatment options. Figure26-01 Female Life Expectancy. Figure27-01 Bone Density Improvement For A Woman Taking HRT. Figure27-02 Cumulative percentage of breast cancers for woman taking HRT from age 50 years and those who have never taken HRT. HRT. Figure27-03 Cumulative percentage of breast cancers for woman taking HRT from age 55 years and those who have never taken HRT. Figure27-04 Causes of Death per Million Women Aged 45-54 years. Figure28-01 Flowchart of HRT options. Figure28-02 Risks and Benefits of HRT. Figure30-01 Prolapse of the Uterus. Figure30-02 Cystocoele Vaginal Prolapse of the Bladder. Figure30-03 Rectocoele Vaginal Prolapse of the Rectum. Figure30-04 Enterocoele Vaginal Prolapse of the Bowel. Figure31-01 Bartholins Cyst. Figure32-01 New Cancer Cases and Deaths In Women In the USA 1997. Figure32-02 New Genital Cancer Cases and Deaths In Women In the USA 1997. Figure32-03 Mortality Statistics For England And Wales, 1993 For Women per Million Population. Figure32-04 Screening tests effect of changing the cut-off point. Figure32-05 Cancer Mortality Rate Changes from 1973 to 1994 (age less than 65 years) in the USA. Figure33-01 Factors to be considered when prescribing hormone treatments. Figure33-02 Alternative Medicine BMJ Front Cover - 2001
DISCLAIMER
The aim of this web site is to provide a general guide and it is not intended as a substitute for a consultation with an appropriate specialist in respect of individual care and treatment.
